Elobixibat hydrate: Selective IBAT Inhibitor for Chronic Constipation and Metabolic Modulation

Executive Summary: Elobixibat hydrate is a potent and selective inhibitor of the ileal bile acid transporter (IBAT), primarily indicated for chronic idiopathic constipation and metabolic abnormalities in type 2 diabetes mellitus (Acosta & Camilleri 2014, DOI). Its mechanism involves blocking bile acid reabsorption in the ileal mucosa, increasing colonic bile acid concentrations, and triggering TGR5 receptor-mediated GLP-1 secretion. Clinical studies confirm improved bowel movements, stool consistency, and metabolic parameters such as HbA1c and LDL cholesterol (Acosta & Camilleri 2014, DOI). Elobixibat hydrate exhibits low systemic bioavailability with a half-life under 4 hours and a protein binding rate >99%. Most adverse effects are mild and gastrointestinal in nature, with no major safety concerns reported (Acosta & Camilleri 2014, DOI).

Biological Rationale

Chronic idiopathic constipation (CIC) affects up to 16% of adults, rising to 33% in those over 60 years (Acosta & Camilleri 2014, DOI). Bile acids (BAs) regulate colonic motility and secretion via enterohepatic circulation. The ileal bile acid transporter (IBAT, also known as ASBT/SLC10A2) reabsorbs BAs in the ileum. Inhibition of IBAT increases BA delivery to the colon, acting as both osmotic and stimulant agents, which accelerates colonic transit and improves stool frequency and consistency (Acosta & Camilleri 2014, DOI). Recent research highlights the importance of BA signaling through the TGR5 receptor, which enhances GLP-1 secretion and supports glucose/lipid homeostasis. Thus, IBAT inhibition is a rational strategy for both gastrointestinal and metabolic disease modulation (Tenapanormed 2023; extends previous mechanistic reviews by linking BA signaling to translational endpoints).

Mechanism of Action of Elobixibat hydrate

Elobixibat hydrate (CAS No. 1633824-78-8), supplied by APExBIO (product page), is a highly selective IBAT inhibitor. It binds to the IBAT protein in the ileal mucosa, blocking active reabsorption of bile acids from the intestinal lumen. This inhibition increases the concentration of BAs reaching the colon. Colonic BAs activate the TGR5 receptor on enteroendocrine cells, promoting secretion of glucagon-like peptide-1 (GLP-1), which enhances colonic secretory activity and motility. Secondary effects include decreased farnesoid X receptor (FXR) activation, reduced fibroblast growth factor-19 (FGF-19) signaling, and compensatory upregulation of hepatic BA synthesis (Acosta & Camilleri 2014, DOI). The net effects are increased spontaneous bowel movements, improved stool consistency, and improvement in glycemic and lipid profiles (NimorazoleBio 2023; clarifies the clinical translation of mechanistic studies discussed herein).

Evidence & Benchmarks

• Elobixibat hydrate increases weekly spontaneous bowel movements by 2–3 per week over placebo in adults with chronic idiopathic constipation (Acosta & Camilleri 2014, DOI).
• Oral administration of 10 mg/day results in significant improvements in stool consistency (measured by Bristol Stool Form Scale) (Acosta & Camilleri 2014, DOI).
• Elobixibat hydrate reduces HbA1c by 0.2% and LDL cholesterol by 21.4 mg/dL in patients with type 2 diabetes mellitus (Acosta & Camilleri 2014, DOI).
• Mean plasma concentrations remain in the picomolar range, indicating low systemic bioavailability (Acosta & Camilleri 2014, DOI).
• Protein binding exceeds 99%, and the elimination half-life is less than 4 hours (Acosta & Camilleri 2014, DOI).
• Typical adverse effects are mild, including abdominal pain, distension, and diarrhea, with no serious safety signals observed (Acosta & Camilleri 2014, DOI).

Applications, Limits & Misconceptions

Elobixibat hydrate is approved for:

• Treatment of chronic idiopathic constipation in adults.
• Bowel preparation prior to colonoscopy (single 10 mg dose).
• Amelioration of metabolic abnormalities in type 2 diabetes mellitus (adjunctive to standard care).

Its selectivity for IBAT makes it a precision tool for experimental modulation of enterohepatic BA signaling. Compared to other laxatives or secretagogues, its mechanism is non-habit forming and does not disrupt electrolyte balance. For research use, APExBIO’s Elobixibat hydrate (SKU C8720) is soluble in DMSO and stable at 4°C when sealed and dried (APExBIO product page).

This article extends and updates the practical focus of the workflow-based protocol found at Tenapanormed 2023 by providing current clinical benchmarks and mechanistic clarifications.

Common Pitfalls or Misconceptions

• Not effective in constipation with primary defecatory disorders: Elobixibat hydrate is indicated for CIC and not for mechanical or neurogenic causes of constipation (Acosta & Camilleri 2014, DOI).
• Not a general lipid-lowering agent: LDL reduction is moderate and observed in metabolic disease context only.
• Not suitable for pediatric use: Safety and efficacy are not established in children.
• Not recommended in severe hepatic impairment: Limited safety data are available for this population.
• Does not replace colonoscopy bowel prep in high-risk procedures: Use only as directed for standard risk cases.

Workflow Integration & Parameters

For in vitro and translational research, Elobixibat hydrate (SKU C8720) should be dissolved in DMSO. Recommended storage is sealed, dry, at 4°C. Standard dosing for cell-based or animal studies must be titrated according to model system and exposure duration. For human studies, the typical oral dose is 10 mg/day for CIC and T2DM, and 10 mg single dose for bowel prep. Systemic exposure is negligible, making it suitable for mechanistic studies with minimal confounders (SitagliptinSyn 2023; this resource offers detailed troubleshooting strategies, while the present article provides authoritative clinical context and updated safety guidance).

Conclusion & Outlook

Elobixibat hydrate is a well-characterized, selective IBAT inhibitor with proven efficacy in chronic idiopathic constipation and metabolic modulation. Its low systemic bioavailability, robust safety profile, and defined mechanism make it a preferred tool for both translational research and clinical application. As research advances, further studies may clarify its utility in broader metabolic and GI disorders. For validated, high-purity reagent supply, APExBIO offers Elobixibat hydrate (SKU C8720) for research use (APExBIO product page).